Thieme E-Journals - Brazilian Journal of Oncology / Abstract
Download PDF
Open Access
CC BY 4.0 · Brazilian Journal of Oncology 2026; 22: s00451812322
DOI: 10.1055/s-0045-1812322
Original Article
Clinical Oncology

Exploring Platinum-Based Treatment Realities: What do Real-World Data Reveal for the Management of Endometrial Cancer in Brazil? – the ECHOS-B Retrospective Study

Authors


Funding The authors declare that the present study was funded by GlaxoSmithKline (GSK) (study number 221709).
Further Information
  Permissions and Reprints All articles of this category

Abstract

Introduction

Real-world data on the treatment and outcomes of patients with endometrial cancer, particularly in Latin America, are limited. We herein present the findings of the Endometrial Cancer Health and Clinical Outcomes Study in Brazil (ECHOS-B), which evaluated the treatment patterns for patients with endometrial cancer.

Materials and Methods

The ECHOS-B retrospective study evaluated data on administrative claims by privately insured women with endometrial cancer in Brazil, who had received first-line platinum-based therapy from January 1, 2015, to December 31, 2019. Treatment patterns, demographic characteristics, and clinical characteristics were described. Disease progression and survival after first-line platinum-based therapy were also assessed.

Results

Out of 1,078 patients, 70.0% (n = 755) were treated with first-line systemic therapy. Of these, 520 (68.9%) received first-line platinum-based therapy (mean age 61.0 ± 12.3 years), and 54.4% (411/755) received first-line carboplatin/paclitaxel, alone or in combination. The mean time until the administration of the first-line platinum-based therapy was 4.8 ± 6.3 months; the mean duration of the first-line therapy was 3.1 ± 2.5 months; and the mean time until the next treatment was of 9.4 ± 7.3 months. Progression occurred in 41.3% of the patients (n = 215/520), with a median time of 18.2 months. The adjusted 1- to 5-year cumulative risks of progression/death were 36.2%, 52.1%, 57.1%, 57.1%, and 59.8% respectively. The 1- to 5-year cumulative risks of death were 10.4%, 23.7%, 27.6%, 31.8%, and 35.4% respectively.

Conclusion

First-line platinum-based therapy for endometrial cancer is frequently used in Brazil; however, high rates of progression were observed, occurring within 2 years. Treatments to prevent or delay progression are needed.

Keywords

Brazil - chemotherapy - drug therapy - endometrial cancer - healthcare administrative claims - real-world

Authors' Contributions

All authors contributed significantly to the work reported. CS: Conceptualization, methodology, validation, investigation, resources, data curation, writing – original draft preparation, writing–review and editing, visualization, project administration, funding acquisition; GA: Conceptualization, methodology, validation, data curation, writing – original draft preparation, writing–review and editing, visualization, supervision, project administration; TLN: Conceptualization, methodology, software, validation, formal analysis, data curation, writing – original draft preparation, writing–review and editing, visualization; JQ: Conceptualization, methodology, software, validation, formal analysis, data curation, writing – original draft preparation, writing–review and editing, visualization; PM: Investigation, resources, writing–review and editing, project administration, funding acquisition; GB: Validation, investigation, writing–review and editing; TP: Validation, investigation, writing–review and editing; MC: Validation, writing–review, and editing; ALARS: Data curation, writing–review and editing. LJ: Conceptualization, writing–review and editing, funding acquisition. All authors took part in drafting, revising, or critically reviewing the manuscript; gave final approval of the version to be published; agreed on the journal to which the article has been submitted; and agreed to be accountable for all aspects of the work.


Supplementary Material



Publication History

Received: 25 November 2024

Accepted: 11 August 2025

Article published online:
11 March 2026

© 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil

Bibliographical Record
Claudia Soares, Gabriela Abreu, Thiago Luiz Nogueira da Silva, Juliana Queiroz, Patrícia Menezes, Graziela Bernardino, Tatiana Pires, Mariano Carrizo, André Luiz Alves Ribeiro de Souza, Laura Jotimliansky. Exploring Platinum-Based Treatment Realities: What do Real-World Data Reveal for the Management of Endometrial Cancer in Brazil? – the ECHOS-B Retrospective Study. Brazilian Journal of Oncology 2026; 22: s00451812322.
DOI: 10.1055/s-0045-1812322
 

  • References

  • 1 World Cancer Research Fund. Endometrial cancer statistics. [cited 2024 October 17]. Available from: https://www.wcrf.org/cancer-trends/endometrial-cancer-statistics/
  • 2 World Health Organization. International Agency for Research on Cancer. Global Cancer Observatory. Corpus uteri. [cited 2024 October 17]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/24-corpus-uteri-fact-sheet.pdf
  • 3 World Health Organization. International Agency for Research on Cancer. Global Cancer Observatory. Brazil. [cited 2024 October 17]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/76-brazil-fact-sheet.pdf
  • 4 World Health Organization. International Agency for Research on Cancer. Global Cancer Observatory. Cancer Tomorrow. Changes of new cases from 2022 to 2050, females, age [0–85+]. [cited 2024 October 17]. Available from: https://gco.iarc.fr/tomorrow/en/dataviz/bars?cancers=24&key=percent&show_bar_mode_prop=0&sexes=2&populations=76_900&years=2050
  • 5 Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J. et al; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer 2016; 26 (01) 2-30
    Search in Google Scholar
  • 6 Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chino J, Chon HS. et al. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. J Natl Compr Canc Netw 2021; 19 (08) 888-895
    Search in Google Scholar
  • 7 Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F. et al; ESMO Guidelines Committee.. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33 (09) 860-877
    Search in Google Scholar
  • 8 Ades F. Access to oncology drugs in Brazil: juggling innovation and sustainability in developing countries. Med Access @. Point Care 2017; 1 (01) e10-e15
    Search in Google Scholar
  • 9 Andrade DAPd, Guimarães APG, Melo ACd, Nogueira-Rodrigues A, Gomes LM, Scaranti M. et al. Management of patients with recurrent/metastatic endometrial cancer: Consensus recommendations from an expert panel from Brazil. Front Oncol 2023; 13: 1133277
    Search in Google Scholar
  • 10 Blanco A, Nogueira-Rodrigues A, Carvalho FM, Giornelli G, Mirza MR. Management of endometrial cancer in Latin America: raising the standard of care and optimizing outcomes. Int J Gynecol Cancer 2024; 34 (08) 1263-1272
    Search in Google Scholar
  • 11 Oncologia Brasil. Anvisa aprova dostarlimabe em monoterapia para o tratamento do carcinoma de endométrio; 2022. [cited 2024 October 17]. Available from: https://oncologiabrasil.com.br/anvisa-aprova-dostarlimabe-em-monoterapia-para-o-tratamento-do-carcinoma-de-endometrio/
  • 12 Paulino E, Melo AC. Clinical characteristics and outcomes of a high-grade endometrial cancer cohort treated at Instituto Nacional de Câncer, Brazil. Rev Bras Ginecol Obstet 2023; 45 (07) e401-e408
    Search in Google Scholar
  • 13 Brüggmann D, Ouassou K, Klingelhöfer D, Bohlmann MK, Jaque J, Groneberg DA. Endometrial cancer: mapping the global landscape of research. J Transl Med 2020; 18 (01) 386
    Search in Google Scholar
  • 14 Orizon. Sobre a Orizon. [cited 2024 October 17]. Available from: https://www.orizonbrasil.com.br/sobre-a-orizon.html
  • 15 National Health Surveillance Agency - Anvisa, Brazilian Health Regulatory Agency - Anvisa. . [cited 2024 October 17]. Available from: https://www.gov.br/anvisa/pt-br/english
  • 16 Friends of Cancer Research. Establishing a Framework to Evaluate Real-World Endpoints. Washington, DC: Friends of Cancer Research; 2018. [cited 2025 February 6]. Available from: https://friendsofcancerresearch.org/wp-content/uploads/RWE_FINAL-7.6.18_1.pdf
    Search in Google Scholar
  • 17 Sousa FGd, Prates ABC, Leal ANA, Xavier LB, Andrade DAPd, Nogueira-Rodrigues A. Identifying areas at risk of endometrial cancer increase in Latin America: development of a geospatial model. Lancet Oncol 2022; 23 (Suppl. 01) S41
    Search in Google Scholar
  • 18 Soares C, Abreu G, Queiroz J, Silva TLNd, Menezes P, Carrizo M. et al. Endometrial cancer treatment and outcomes in Argentina: ECHOS-A real-world study. Gynecol Oncol Rep 2024; 54: 101457
    Search in Google Scholar
  • 19 Monk BJ, Smith G, Lima J, Long GH, Alam N, Nakamura H. et al. Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records. Gynecol Oncol 2022; 164 (02) 325-332
    Search in Google Scholar
  • 20 Heffernan K, Nikitas FS, Shukla U, Camejo HS, Knott C. Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis. Gynecol Oncol 2022; 166 (02) 317-325
    Search in Google Scholar
  • 21 Akada K, Koyama N, Miura T, Fukunaga E, Miura Y, Aoshima K, Fujiwara K. Real-world database analysis of the characteristics and treatment patterns of patients with endometrial cancer in Japan. Curr Med Res Opin 2021; 37 (07) 1171-1178
    Search in Google Scholar
  • 22 Prabhu VS, Kelkar SS, Zhang J, Ogando YM, Miles N, Marth C. 2022-RA-702-ESGO real-world treatment patterns and outcomes in recurrent or advanced endometrial cancer patients initiating 1st-line systemic therapy in Europe: a retrospective chart review study. Int J Gynecol Cancer 2022; 32 (Suppl. 02) A104-A105
    Search in Google Scholar
  • 23 Silva B, Hens N, Gusso G, Lagaert S, Macinko J, Willems S. Dual use of public and private health care services in Brazil. Int J Environ Res Public Health 2022; 19 (03) 1829
    Search in Google Scholar
  • 24 Anton C, Kleine RT, Mayerhoff E, Diz MdPE, Freitas Dd, Carvalho HdA. et al. Ten years of experience with endometrial cancer treatment in a single Brazilian institution: Patient characteristics and outcomes. PLoS One 2020; 15 (03) e0229543
    Search in Google Scholar
  • 25 Paulino E, de Melo AC, Nogueira-Rodrigues A, Thuler LCS. Gynecologic cancer in Brazil and the law of sixty days. J Gynecol Oncol 2018; 29 (03) e44
    Search in Google Scholar
  • 26 Gioia S, Brigagao L, Rocha M, Goss P. Patient navigation: fighting for the rights of breast cancer patients in Brazil. Mastology 2021; 31: e20200068
    Search in Google Scholar
  • 27 Paulino E, de Melo AC, Silva-Filho AL, Maciel LdF, Thuler LCS, Goss P, Nogueira-Rodrigues A. Panorama of gynecologic cancer in Brazil. JCO Glob Oncol 2020; 6: 1617-1630
    Search in Google Scholar
  • 28 Candido EC, Veiga Junior NN, Minari MP, Toledo MCS, Yela DA, Teixeira JC. Malignant uterine neoplasms attended at a Brazilian regional hospital: 16-years profile and time elapsed for diagnosis and treatment. Rev Bras Ginecol Obstet 2021; 43 (02) 137-144
    Search in Google Scholar
  • 29 Liu J, Emond B, Maiese EM, Lafeuille M-H, Lefebvre P, Ghelerter I. et al. Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States. Curr Med Res Opin 2022; 38 (11) 1935-1945
    Search in Google Scholar
  • 30 Huijgens AN, Mertens HJ. Factors predicting recurrent endometrial cancer. Facts Views Vis ObGyn 2013; 5 (03) 179-186
    Search in Google Scholar
  • 31 Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R. et al. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2023; 21 (02) 181-209
    Search in Google Scholar
  • 32 Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH. et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin 2019; 69 (04) 258-279
    Search in Google Scholar
  • 33 Di Tucci C, Capone C, Galati G, Iacobelli V, Schiavi MC, Di Donato V. et al. Immunotherapy in endometrial cancer: new scenarios on the horizon. J Gynecol Oncol 2019; 30 (03) e46
    Search in Google Scholar
  • 34 Post CCB, Westermann AM, Bosse T, Creutzberg CL, Kroep JR. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Crit Rev Oncol Hematol 2020; 152: 102973
    Search in Google Scholar
  • 35 Rubinstein M, Shen S, Monk BJ, Tan DSP, Nogueira-Rodrigues A, Aoki D. et al. Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer. Gynecol Oncol 2022; 167 (03) 540-546
    Search in Google Scholar
  • 36 Martins D, O'Sullivan DE, Boyne DJ, Cheung WY, Allonby O, Habash M. et al. Understanding characteristics, treatment patterns, and clinical outcomes for individuals with advanced or recurrent endometrial cancer in Alberta, Canada: a retrospective, population-based cohort study. Curr Oncol 2023; 30 (02) 2277-2289
    Search in Google Scholar
  • 37 Rubinstein M, Halpenny D, Makker V, Grisham RN, Aghajanian C, Cadoo K. Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience. Gynecol Oncol Rep 2019; 28: 120-123
    Search in Google Scholar
  • 38 Merck & Co., Inc.. Keytruda: Highlights of prescribing information. [cited 2024 October 17]. Available from: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
  • 39 European Medicines Agency. Keytruda – pembrolizumab. [cited 2024 October 17]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda
  • 40 GlaxoSmithKline plc. Jemperli: Highlights of prescribing information. [cited 2024 October 17]. Available from: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Jemperli/pdf/JEMPERLI-PI-MG.PDF
  • 41 European Medicines Agency. Jemperli – dostarlimab. [cited 2024 October 17]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli
  • 42 Powell MA, Bjørge L, Willmott L, Novák Z, Black D, Gilbert L. et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol 2024; 35 (08) 728-738
    Search in Google Scholar
  • 43 Agência Nacional de Vigilância Sanitária (ANVISA). Jemperli (dostarlimabe): nova indicação. [cited 2024 October 17]. Available from: https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/jemperli-dostarlimabe-nova-indicacao